Integer to Highlight Integrated R&D Solutions and Expanded Coating Capabilities During MD&M West 2026

Rhea-AI Summary

Integer (NYSE: ITGR) will exhibit at MD&M West 2026 in Anaheim, Feb 3–5, unveiling an expanded 20 x 50 sq. ft. booth #3201 and showcasing R&D Velocity, an integrated R&D ecosystem linking design, prototyping and manufacturing to accelerate device manufacturability.

Integer will also highlight expanded medical coatings capabilities after recent acquisitions, plus cardiac rhythm, neuromodulation, and cardio/vascular product platforms.

Key Figures

Booth size: 20 x 50 sq. ft. Prototype turnaround: Two weeks Event dates: Feb 3–5, 2026 +5 more

8 metrics

Booth size 20 x 50 sq. ft. New MD&M West 2026 booth #3201

Prototype turnaround Two weeks Rapid prototyping under R&D Velocity ecosystem

Event dates Feb 3–5, 2026 MD&M West 2026 exhibition in Anaheim

Share repurchase $200 million Share buyback authorization on Nov 4, 2025

Battery recharge time 30 minutes Xcellion Gen 3 Fast Charge Lithium Ion battery (NANS 2026 news)

CEO RSU grant 19,429 RSUs Equity award to CEO Payman Khales on Jan 16, 2026

Share price $85.79 Pre-news price vs 52-week range $62–$146.36

Market cap $3,021,713,858 Equity value prior to MD&M West 2026 announcement

Market Reality Check

Price: $85.90 Vol: Volume 309,814 vs 20-day ...

low vol

$85.90 Last Close

Volume Volume 309,814 vs 20-day average 514,613 (relative volume 0.6) ahead of this event-focused news. low

Technical Shares at $85.79 are trading below the $100.42 200-day MA and about 41.38% under the 52-week high.

Peers on Argus

ITGR was down 0.52% with key peers also slightly negative: LIVN -0.17%, TMDX -1....

ITGR was down 0.52% with key peers also slightly negative: LIVN -0.17%, TMDX -1.07%, BRKR -1.14%, HAE -0.31%, GKOS -3.94%. Scanner data shows no active sector-wide momentum.

Historical Context

5 past events · Latest: Jan 22 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 22	Earnings call scheduling	Neutral	-1.7%	Announcement of Q4 and full-year 2025 results webcast details.
Jan 14	Technology showcase	Positive	+2.4%	Exhibit of neuromodulation and miniaturized AIMD innovations at NANS 2026.
Nov 18	Investor conferences	Neutral	+1.0%	Participation by executives in two early December healthcare conferences.
Nov 4	Share repurchase plan	Positive	+2.5%	Board authorization of a <b>$200 million</b> common stock repurchase program.
Oct 24	CEO transition	Positive	-1.3%	Planned transition to new President and CEO Payman Khales.

Pattern Detected

Recent news has often seen modest price responses, with clearly shareholder-friendly actions like the $200 million buyback drawing positive moves, while leadership changes and scheduling announcements have sometimes coincided with mild declines.

Recent Company History

Over the past few months, Integer has focused on investor outreach, technology showcases, capital returns, and leadership transition. In October 2025, a new CEO, Payman Khales, assumed the role with a small negative reaction. A $200 million buyback announced on Nov 4, 2025 drew a positive move. Conference participation and neuromodulation innovation news in late 2025 and early 2026 produced modest gains or declines, indicating generally measured market reactions to operational and event-related updates similar to today’s trade show announcement.

Market Pulse Summary

This announcement emphasizes Integer’s integrated R&D Velocity ecosystem, rapid prototyping in as li...

Analysis

This announcement emphasizes Integer’s integrated R&D Velocity ecosystem, rapid prototyping in as little as two weeks, and an expanded coatings portfolio following multiple acquisitions. Historically, event- and innovation-focused updates have produced modest, mixed price reactions. Investors may track how these capabilities influence future orders, the impact of the prior $200 million repurchase authorization, and whether trading below the $100.42 200-day MA and roughly 41.38% under the 52-week high persists as new commercial opportunities develop.

Key Terms

cdmo, hydrophilic coatings, parylene, neurovascular, +2 more

6 terms

cdmo financial

"one of the largest medical device contract development and manufacturing organizations (CDMO) in the world"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

hydrophilic coatings technical

"Integer will also showcase its full coatings portfolio, including PTFE, PTFE alternatives, hydrophilic coatings, parylene"

Hydrophilic coatings are thin surface layers that attract and hold a film of water, making medical device surfaces slippery and less likely to catch on tissue, blood, or other biological materials. For investors, they matter because coatings can improve patient outcomes, reduce complications and procedure time, and help a product stand out in the market—like a nonstick pan making a job easier and more reliable—potentially boosting sales, pricing power, and regulatory acceptance.

parylene technical

"full coatings portfolio, including PTFE, PTFE alternatives, hydrophilic coatings, parylene, and advanced surface-modification"

Parylene is a family of ultra-thin, clear plastic-like coatings applied to electronic parts and medical devices using a vapor process, forming an even, pinhole-free protective film. Investors care because it acts like a microscopic raincoat—shielding components from moisture, corrosion and chemical exposure—so its use can improve product reliability, extend lifespan, affect manufacturing steps and costs, and influence regulatory approval and warranty risk.

neurovascular medical

"advancing structural heart delivery systems, neurovascular catheters, electrophysiology tools"

Neurovascular describes the blood vessels and circulation that supply the brain, spinal cord and other parts of the nervous system, and the medical devices or treatments that protect or repair them. Investors care because disorders of this system—like strokes or aneurysms—drive demand for specialized drugs, devices and procedures; think of it as the plumbing and roads for the brain, where improvements can reduce risk, cut costs, and create market opportunities.

electrophysiology medical

"structural heart delivery systems, neurovascular catheters, electrophysiology tools, peripheral vascular therapies"

The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

neuromodulation medical

"cardiac rhythm management and neuromodulation devices, Integer helps customers design products"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

AI-generated analysis. Not financial advice.

Attendees Invited to Experience Integer’s New Booth #3201

PLANO, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, will exhibit during MD&M West 2026 in Anaheim, Calif., Feb. 3 – 5.

Integer will unveil a significantly expanded 20 x 50 sq. ft. new booth #3201, showcasing the company’s full range of customer solutions.

On prominent display will be R&D Velocity, Integer’s integrated R&D ecosystem connecting design, prototyping and manufacturing to help medical device companies develop products that are manufacturable from the start, accelerating the time between design and manufacturability.

“Whether you’re advancing structural heart delivery systems, neurovascular catheters, electrophysiology tools, peripheral vascular therapies, or cardiac rhythm management and neuromodulation devices, Integer helps customers design products right the first time — with production in mind,” said Andrew Senn, President, Cardio & Vascular. “Through expert engineers, advanced labs, rapid prototyping, development and scalable manufacturing under one ecosystem, Integer R&D Velocity helps medical device companies bridge the gap between early concepts and real-world production, reducing iterations and expediting development cycles.”

The company will showcase several solutions – delivered through a network of locations globally – that are central to R&D Velocity, including:

• Differentiated Technology Platforms: Proven product technologies that enable, accelerate and de-risk the development of our customers’ next generation devices
• Global Capabilities and Expertise: Specialized labs and integrated manufacturing all in one ecosystem along with dedicated engineers and global centers of excellence to accelerate every phase of development.
• Ease of Manufacturability: Designs optimized early to scale seamlessly, reducing rework and accelerating launch.
• Rapid Prototyping: Engineer-to-engineer collaboration delivering prototypes in as little as two weeks.

Integer will additionally highlight a range of key product areas and innovations during MD&M West, including:

• Integer Medical Coatings: The company continues to expand its role as a fully integrated coating partner for medical devices, strengthening its ability to deliver end-to-end surface-modification solutions. Integer will also showcase its full coatings portfolio, including PTFE, PTFE alternatives, hydrophilic coatings, parylene, and advanced surface-modification technologies. Following the acquisitions of Precision Coating, VSi Parylene, and certain Biocoat assets last year, Integer has further strengthened its position as a fully integrated coating partner for medical devices.
  
• Cardiac Rhythm Management and Neuromodulation: Miniaturized technologies for finished IPG systems, as well as Gen 3 Li-Ion and Gen 2 CFx batteries.
  
• Cardio and Vascular: A full range of electrophysiology, structural heart, and neurovascular product solutions including complex catheters, guidewires, steerable introducers and sheaths, therapy delivery systems and implant technologies.

“With an end-to-end ecosystem that connects design, development and global manufacturing, Integer empowers customers to streamline development and bring high-quality medical devices to market more efficiently,” said Jim Stephens, President, Cardiac Rhythm Management and Neuromodulation. “We’re excited to share our latest capabilities during MD&M West and encourage attendees to meet the team and see what’s possible at booth #3201.”

Learn more about Integer at www.integer.net.

About Integer^®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, Integer is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company’s brands include Greatbatch Medical^® and Lake Region Medical^®. Additional information is available at www.integer.net.

Investor Relations:	Media Relations:
Kristen Stewart	Misty Tippen
kristen.stewart@integer.net	misty.tippen@integer.net
551.337.3973	469.536.6702

FAQ

What will Integer (ITGR) present at MD&M West 2026 on Feb 3–5?

Integer will showcase an expanded 20 x 50 sq. ft. booth #3201 highlighting integrated R&D and coatings. According to Integer, the exhibit features R&D Velocity linking design, prototyping and manufacturing and demonstrates coatings, cardiac rhythm, neuromodulation, and cardio/vascular capabilities.

What is Integer R&D Velocity and how does it affect product development for ITGR customers?

R&D Velocity is Integer's integrated ecosystem connecting design, prototyping and scalable manufacturing to reduce iterations. According to Integer, it aims to optimize manufacturability early, speed development cycles, and help customers bring production-ready devices to market faster.

How has Integer (ITGR) expanded its medical coatings capabilities prior to MD&M West 2026?

Integer expanded coatings by acquiring Precision Coating, VSi Parylene, and certain Biocoat assets last year. According to Integer, these additions strengthen its end-to-end surface-modification offerings including PTFE, hydrophilic, parylene, and advanced coatings.

Which product areas will Integer (ITGR) highlight at MD&M West 2026 and why are they important?

Integer will highlight cardiac rhythm, neuromodulation, electrophysiology, structural heart and neurovascular solutions. According to Integer, showcasing these areas demonstrates integrated design-to-manufacturing capabilities across finished IPG systems, batteries, catheters, guidewires and implant technologies.

Where can investors and attendees learn more about Integer (ITGR) capabilities after MD&M West?

Attendees can visit booth #3201 at MD&M West and access online resources to learn more. According to Integer, additional information and corporate capabilities are available through the company website and its global centers of excellence.